Meox1 promotes hepatocellular carcinoma progression potentially via regulation of cell cycle and p21 expression.
OpenAlex 토픽 ·
Glutathione Transferases and Polymorphisms
DNA Repair Mechanisms
Redox biology and oxidative stress
Meox1 is aberrantly expressed in several malignancies, but its role in hepatocellular carcinoma (HCC) remains unclear.
APA
Jie Ruan, Ying Xie, et al. (2026). Meox1 promotes hepatocellular carcinoma progression potentially via regulation of cell cycle and p21 expression.. Cell adhesion & migration, 20(1), 2658289. https://doi.org/10.1080/19336918.2026.2658289
MLA
Jie Ruan, et al.. "Meox1 promotes hepatocellular carcinoma progression potentially via regulation of cell cycle and p21 expression.." Cell adhesion & migration, vol. 20, no. 1, 2026, pp. 2658289.
PMID
42002886
Abstract
Meox1 is aberrantly expressed in several malignancies, but its role in hepatocellular carcinoma (HCC) remains unclear. This study aimed to investigate the effects of Meox1 on HCC cells and explore the underlying molecular mechanisms. Cell proliferation, colony formation, migration, invasion, and cell cycle distribution were assessed by CCK-8, clonogenic, Transwell, and flow cytometry assays, respectively. Protein expression was examined by Western blotting. Meox1 silencing significantly inhibited proliferation, clonogenic capacity, migration and invasion of HCC cells. Cell cycle analysis showed a reduction in G1-phase cells with a marked accumulation in the G2 phase following Meox1 knockdown. Western blot analysis revealed that suppression of Meox1 reduced p21CIP1/WAF1 expression. Meox1 contributest to HCC progression and may represent a potential therapeutic target.
MeSH Terms
Humans; Carcinoma, Hepatocellular; Liver Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cell Proliferation; Disease Progression; Cell Movement; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Cell Cycle; Hep G2 Cells; Neoplasm Invasiveness
같은 제1저자의 인용 많은 논문 (5)
- Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study.
- Low-dose dihydroartemisinin resensitizes lung cancer cells to cisplatin by suppressing interleukin-6 release by macrophages.
- Expression profiling reveals coordinated dysregulation of autophagy-associated proteins in marginal zone lymphoma and therapeutic implications.
- MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.
- Association Between Seven Selected Genetic Polymorphisms in DNA Repair-Related Genes and Breast Cancer Risk: Evidence from a Comprehensive Meta-analysis Including 96 Studies.